Vor Bio announced on August 4, 2025, the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies.
He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer, overseeing commercial and medical affairs and achieving approximately $1.8 billion in net product revenue in 2024. His experience includes leading or supporting over a dozen product launches, such as INCIVEK at Vertex Pharmaceutics and multiple global rollouts at Gilead Sciences and Biogen Inc.
Mr. Murray's track record of building high-performing commercial organizations and executing successful product launches will be instrumental as Vor Bio prepares for the potential commercialization of telitacicept. This appointment is a key step in shaping the company's broader growth strategy in the autoimmune disease market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.